STK11 and KEAP1 mutations confer worse outcomes with immunotherapy among patients with KRASMUT but not among patients with KRASWT [56], provoking an accrual of neutrophils with T cell suppressive effects and tumor-promoting cytokines [16,55]. This evidence concerns the gene KEAP1 and neoplasm.